Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD2373-Arm 1 · 1 trial · 1 indication
To assess the effect of AZD2373 versus placebo in reducing albuminuria
| Arm | Type | Description |
|---|---|---|
| Part A - Placebo group | PLACEBO_COMPARATOR | Participants will be randomized at a 1:1:1 ratio to 3 study treatment arms. Participants will receive SC injection of the assigned dose. |
| Part A - AZD2373 - Arm 1 | EXPERIMENTAL | Participants will be randomized at a 1:1:1 ratio to 3 study treatment arms. Participants will receive SC injection of the assigned dose. |
| Part A - AZD2373 - Arm 2 | EXPERIMENTAL | Participants will be randomized at a 1:1:1 ratio to 3 study treatment arms. Participants will receive SC injection of the assigned dose. |
| Part B - AZD2373 Arm 1 | EXPERIMENTAL | Participants will be randomized at a 4:1 ratio to 2 study treatment arms. Participants will receive SC injection of the assigned dose |
| Part B - Placebo group | PLACEBO_COMPARATOR | Participants will be randomized at a 4:1 ratio to 2 study treatment arms. Participants will receive SC injection of the assigned dose |
| Name | Type | Description |
|---|---|---|
| AZD2373-Arm 1 | COMBINATION_PRODUCT | Accessorized Pre-Filled Syringe (Solution for injection) |
| AZD2373-Arm 2 | COMBINATION_PRODUCT | Accessorized Pre-Filled Syringe (Solution for injection) |
| Placebo | COMBINATION_PRODUCT | Accessorized Pre-Filled Syringe (Solution for injection). |
| APOL1 Genotyping Clinical Trial Assay | DEVICE | The APOL1 Genotyping Clinical Trial Assay, an investigational use only qualitative Polymerase Chain Reaction invitro diagnostic assay, discriminates between the rs73885319 G1(S342G) and rs71785313 G2 genotypes within the APOL1 gene from DNA extracted from whole blood. |
Inclusion Criteria: * Age: Male and female participants of African descent (including, but not limited to, Black, Black African, Black Caribbean, African American, Afro-Caribbean, Afro-Latino, West African, Mixed Black backgrounds, or other self-identified African diaspora heritage) aged 18 to 70 y...
AZD2373-Arm 1 is an investigational small molecule being developed for the treatment of APOL1-Mediated Kidney Disease, a condition in the nephrology therapeutic area. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
AZD2373-Arm 1 is a small molecule being studied for APOL1-Mediated Kidney Disease. The specific molecular target of AZD2373-Arm 1 has not been disclosed in the available information, so its precise mechanism of action is not described here.
AZD2373-Arm 1 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting a Phase 2 clinical trial to evaluate the drug in patients with APOL1-Mediated Kidney Disease.
AZD2373-Arm 1 is in Phase 2 clinical development. It is an investigational drug and has not yet been approved by the FDA or other regulatory agencies. The ongoing Phase 2 trial is a dose-ranging study assessing safety, tolerability, and efficacy in participants with APOL1-Mediated Kidney Disease.
AZD2373-Arm 1 is being evaluated in a Phase 2 clinical trial with the identifier NCT06824987. This is a randomized, double-blind, placebo-controlled study titled 'Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease.' The trial is currently recruiting participants in the United States and United Kingdom, with an enrollment target of 136 patients.
AZD2373-Arm 1 is a specific arm of the clinical trial studying AZD2373. The trial NCT06824987 evaluates AZD2373 in multiple dose arms, with 'Arm 1' referring to one of the treatment groups. The drug substance is AZD2373, and AZD2373-Arm 1 denotes the particular study arm in which it is administered.